Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Common Equity (2020 - 2025)

Arcutis Biotherapeutics has reported Common Equity over the past 6 years, most recently at $189.5 million for Q4 2025.

  • Quarterly results put Common Equity at $189.5 million for Q4 2025, up 20.27% from a year ago — trailing twelve months through Dec 2025 was $189.5 million (up 20.27% YoY), and the annual figure for FY2025 was $189.5 million, up 20.27%.
  • Common Equity for Q4 2025 was $189.5 million at Arcutis Biotherapeutics, up from $158.1 million in the prior quarter.
  • Over the last five years, Common Equity for ARQT hit a ceiling of $451.0 million in Q1 2021 and a floor of $46.7 million in Q3 2023.
  • Median Common Equity over the past 5 years was $188.0 million (2024), compared with a mean of $208.3 million.
  • Biggest five-year swings in Common Equity: plummeted 82.75% in 2023 and later soared 235.3% in 2024.
  • Arcutis Biotherapeutics' Common Equity stood at $297.7 million in 2021, then dropped by 29.59% to $209.6 million in 2022, then crashed by 57.69% to $88.7 million in 2023, then skyrocketed by 77.68% to $157.5 million in 2024, then grew by 20.27% to $189.5 million in 2025.
  • The last three reported values for Common Equity were $189.5 million (Q4 2025), $158.1 million (Q3 2025), and $139.0 million (Q2 2025) per Business Quant data.